EugeneAndrewBauerMD
Dermatology • Stanford, CAEmeritus Faculty, Academic Council, Dermatology, Stanford University Medical Center
Dr. Bauer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Stanford University
Department of Dermatology
Stanford, CA 94305Phone+1 310-721-3364
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Dermatology, 1968 - 1974- Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 1967 - 1968
Northwestern University The Feinberg School of MedicineClass of 1967
Certifications & Licensure
CA State Medical License 1988 - 2026
MO State Medical License 1971 - 2017- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Elected Member Institute of Medicine/National Academy of Medicine, 1997
- Elected Member ASCI, AAP, 1980, 1984
Publications & Presentations
PubMed
- 15 citationsHuman Skin Fibroblasts in Culture: Procollagen Synthesis in the Presence of Sera from Normal Human Subjects and from Patients with Dermal FibrosesElaine M. L. Tan, Jouni Uitto, Eugene A. Bauer, Arthur Z. Eisen
The Journal of Investigative Dermatology. 1981-06-01 - 545 citationsHuman fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein.Gregory I. Goldberg, Scott M. Wilhelm, Annemarie Kronberger, Eugene A. Bauer, Gregory A. Grant
The Journal of Biological Chemistry. 1986-05-15 - 591 citationsInherited epidermolysis bullosa: Updated recommendations on diagnosis and classificationJo-David Fine, Leena Bruckner-Tuderman, Robin A.J. Eady, Eugene A. Bauer, Johann W. Bauer
Journal of the American Academy of Dermatology. 2014-06-01
Press Mentions
Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic DermatitisSeptember 28th, 2022- Ex-Dermira Founders Pick up $83M for Evommune to Advance Programs in-Licensed from Lilly's DermiraSeptember 9th, 2021
Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development of Food Allergy TherapeuticsFebruary 24th, 2020- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
